BACKGROUND: The multikinase inhibitor sunitinib has enhanced the treatment of renal cell carcinoma and gastrointestinal stromal tumor through an improved clinical response with decreased systemic toxicities. However, sunitinib is frequently associated with dermatological adverse reactions. The physical and psychosocial impact of frequent dermatological toxicities can affect consistent antineoplastic therapy and quality of life. PATIENTS AND METHODS: Dermatological adverse reaction information was compiled from Pfizer Medical Information and from abstracts from the 2007 American Society of Clinical Oncology annual meeting, Prostate Cancer Symposium, and Gastrointestinal Cancers Symposium. Published clinical trials of sunitinib in MEDLINE, Cochrane Library, Cochrane Controlled Trials Register, and EMBASE Drugs and Pharmacology databases were also included. Information was accessed on or before June 30, 2007. RESULTS: In the pooled analysis, all-grade hand-foot skin reaction occurred in 19% of patients (5% grades 3-4), skin discoloration in 28% (0% grades 3-4), dry skin in 16% (1% grades 3-4), skin rash in 13% (1% grades 3-4), dermatitis in 8% (2% grades 3-4), hair color changes in 10% (0% grades 3-4), alopecia in 6% (0% grades 3-4), and phototoxicity in <0.1%. CONCLUSIONS: Dermatological reactions associated with sunitinib occur frequently. Evidence-based treatment recommendations are needed in order to maximize quality of life and optimize clinical outcome.
BACKGROUND: The multikinase inhibitor sunitinib has enhanced the treatment of renal cell carcinoma and gastrointestinal stromal tumor through an improved clinical response with decreased systemic toxicities. However, sunitinib is frequently associated with dermatological adverse reactions. The physical and psychosocial impact of frequent dermatological toxicities can affect consistent antineoplastic therapy and quality of life. PATIENTS AND METHODS: Dermatological adverse reaction information was compiled from Pfizer Medical Information and from abstracts from the 2007 American Society of Clinical Oncology annual meeting, Prostate Cancer Symposium, and Gastrointestinal Cancers Symposium. Published clinical trials of sunitinib in MEDLINE, Cochrane Library, Cochrane Controlled Trials Register, and EMBASE Drugs and Pharmacology databases were also included. Information was accessed on or before June 30, 2007. RESULTS: In the pooled analysis, all-grade hand-foot skin reaction occurred in 19% of patients (5% grades 3-4), skin discoloration in 28% (0% grades 3-4), dry skin in 16% (1% grades 3-4), skin rash in 13% (1% grades 3-4), dermatitis in 8% (2% grades 3-4), hair color changes in 10% (0% grades 3-4), alopecia in 6% (0% grades 3-4), and phototoxicity in <0.1%. CONCLUSIONS: Dermatological reactions associated with sunitinib occur frequently. Evidence-based treatment recommendations are needed in order to maximize quality of life and optimize clinical outcome.
Authors: Robert J Motzer; Brian I Rini; Ronald M Bukowski; Brendan D Curti; Daniel J George; Gary R Hudes; Bruce G Redman; Kim A Margolin; Jaime R Merchan; George Wilding; Michelle S Ginsberg; Jennifer Bacik; Sindy T Kim; Charles M Baum; M Dror Michaelson Journal: JAMA Date: 2006-06-07 Impact factor: 56.272
Authors: Edwin P Rock; Vicki Goodman; Janet X Jiang; Kooros Mahjoob; S Leigh Verbois; David Morse; Ramzi Dagher; Robert Justice; Richard Pazdur Journal: Oncologist Date: 2007-01
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Dirk Strumberg; Jeffrey W Clark; Ahmad Awada; Malcolm J Moore; Heike Richly; Alain Hendlisz; Hal W Hirte; Joseph P Eder; Heinz-Josef Lenz; Brian Schwartz Journal: Oncologist Date: 2007-04
Authors: Walter Fiedler; Hubert Serve; Hartmut Döhner; Michael Schwittay; Oliver G Ottmann; Anne-Marie O'Farrell; Carlo L Bello; Randy Allred; William C Manning; Julie M Cherrington; Sharianne G Louie; Weiru Hong; Nicoletta M Brega; Giorgio Massimini; Paul Scigalla; Wolfgang E Berdel; Dieter K Hossfeld Journal: Blood Date: 2004-09-30 Impact factor: 22.113
Authors: Nienke A G Lankheet; Alwin D R Huitema; Henk Mallo; Sandra Adriaansz; John B A G Haanen; Jan H M Schellens; Jos H Beijnen; Christian U Blank Journal: Eur J Clin Pharmacol Date: 2013-08-31 Impact factor: 2.953
Authors: Rena C Zuo; Andrea B Apolo; John J DiGiovanna; Howard L Parnes; Corrine M Keen; Swati Nanda; William L Dahut; Edward W Cowen Journal: JAMA Dermatol Date: 2015-02 Impact factor: 10.282
Authors: Anna E Kersh; Spencer Ng; Yun Min Chang; Maiko Sasaki; Susan N Thomas; Haydn T Kissick; Gregory B Lesinski; Ragini R Kudchadkar; Edmund K Waller; Brian P Pollack Journal: J Clin Pharmacol Date: 2017-11-14 Impact factor: 3.126
Authors: D M Barrios; G S Phillips; A Freites-Martinez; M Hsu; K Ciccolini; A Skripnik Lucas; M A Marchetti; A M Rossi; E H Lee; L Deng; A Markova; P L Myskowski; M E Lacouture Journal: J Eur Acad Dermatol Venereol Date: 2020-02-05 Impact factor: 6.166
Authors: M E M Dolman; Stefan Harmsen; Ebel H E Pieters; Rolf W Sparidans; Marie Lacombe; Bálint Szokol; László Orfi; György Kéri; Gert Storm; Wim E Hennink; Robbert J Kok Journal: Int J Nanomedicine Date: 2012-01-31